Page 52 - Read Online
P. 52

Genvigir et al. J Transl Genet Genom 2020;4:320-55  I  http://dx.doi.org/10.20517/jtgg.2020.37                               Page 337

             Ref.   [49]  [65]  [13]       [14]           [59]     [37]      [29]   [27]       [38]



             Clinical outcomes  No association of  SLCO1B1 c.388A>G and   463C>A variants with   neutrophil counts  No association of   SLCO1B3 c.334T>G (or   699G>A) variant with   diarrhea   No association of   SLCO1B3 c.334T>G   variant with AR or   adverse events  -  No association of  SLCO1B3 c.334T>G (or   699G>A) variant with   -  No association of   SLCO1B3 c.334T>G   variant with AR or   adverse events  No association of   SLCO1B3 c.334T>G and   rs1104585 variant








             Pharmacokinetics  No association of  SLCO1B1 c.388A>G and   463C>A variants with   MPA exposure (AUC)  SLCO1B3 c.334GG (699AA)   genotype was associated   with higher exposure to   MPA (AUC 6-12)  -  SLCO1B3 c.334GG  genotype was associated   with lower MPA peak   concentration and   exposure (AUC 0-12 ) and  higher MPAG/MPA ratio,   on cyclosporine-free   treatment (n = 70)  No association of   SLCO1B3 c.334T>G (or   699G>A) variant with  exposure to MPA, MP








            Immunosuppressive   regimen  MMF  Tacrolimus  Corticosteroid-free  One-year follow-up  MMF  Tacrolimus  Corticosteroids  At day 28  MMF  Cyclosporine  Tacrolimus  mTOR inhibitor   Corticosteroids  One-year follow-up  MMF  Cyclosporine  Tacrolimus  Sirolimus  Corticosteroids   At a point between 3-6   months  MMF  Cyclosporine  Tacrolimus  Corticosteroids   One-year follow-up  MMF  Cyclosporine   Corticosteroids  EC-MPS  Cyclosporine  Corticosteroids  Six-month












             Population  21 adult patients   (Canada)  87 adult patients  (Japan)  (France)  185 patients  (France)  338 adult patients   37 adult patients  (China)  189 adult patients  (France)  284 pediatric and young   adult patients (USA)  408 adult patients   (China)








             Study design  Prospective  Prospective  Retrospective (Transgene 218 adult patients  study)  Prospective (included   multicenter Apomygre   study)  Prospective (FDCC   Study)  Prospective,  Multicenter  (Case-control)  Prospective, multicenter   (Dominos study)  Retrospective (Case-  Control), multicenter  Retrospective








             Allele frequency  c.388G: 48%  463A: 10%  c.334T: 34%   699G: 34%  c.334T: 17%  c.334T: 18%  767C: 15%  c.334T: 19%  c.334T: 30%  c.334T: 15%  -  c.334T: 29%








                        rs4149117 (c.334T>G)  rs7311358  (c.699G>A)  rs1104585  rs60140950   (c.767G>C)

             Variant






             Gene       SLCO1B3
   47   48   49   50   51   52   53   54   55   56   57